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PERKHIDMATAN PEMANTAUAN DRUG TERAPEUTIK DI MALAYSIA: 
PRAKTIS SEMASA DAN PENILAIAN KOS 
 
ABSTRAK 
 
Pemantauan drug terapeutik (TDM) telah dikenalpasti sebagai satu alat klinikal yang 
berguna dalam terapi drug. Walaupun ia telah bermula sejak tahun 1980an lagi di 
negara ini, hanya sedikit sahaja kajian yang telah dilakukan mengenainya. Oleh yang 
demikian, kajian ini bertujuan untuk menilai amalan perkhidmatan TDM di hospital-
hospital di Malaysia dan mengenalpasti kos dan hasilan klinikal perkhidmatan ini 
dalam pesakit yang dimasukkan ke hospital. Kajian ini terdiri dari dua bahagian yang 
berkait rapat. Bahagian pertama mengenalpasti amalan semasa perkhidmatan TDM 
dalam hospital-hospital di Malaysia menggunakan borang soal-selidik. Soal-selidik 
dihantar kepada 128 hospital di Malaysia. Data yang dikumpulkan termasuk ciri-ciri 
umum hospital, aktiviti-aktiviti pentadbiran, klinikal dan makmal berkaitan 
perkhidmatan TDM. Dari 121 hospital yang memberikan respon kepada soal-selidik 
tersebut, 34 hospital (28.1%) memberikan perkhidmatan itu dengan makmal TDM 
mereka sendiri, 44 hospital (36.4%) menggunakan makmal hospital lain dan 43 
hospital (35.5%) tidak memberikan perkhidmatan tersebut. Bahagian kedua kajian ini 
dijalankan untuk menilai kos menyediakan perkhidmatan TDM di kalangan pesakit 
yang dimasukkan ke hospital. Penilaian ini dijalankan di dua buah hospital 
menggunakan kaedah pengumpulan data secara retrospektif. Data dari pesakit 
dewasa yang dimasukkan ke hospital yang didiagnos bronkopneumonia dan dirawat 
dengan gentamisin di antara tahun-tahun 2001 hingga 2005 dikaji. Data yang diambil 
dari Hospital Universiti Sains Malaysia (HUSM) digunakan untuk menentukan kos 
yang dikaitkan dengan pemberian perkhidmatan TDM tersebut. Data yang dikumpul 
 xxi
dari Hospital Kulim digunakan untuk membandingkan kos dan hasilan antara 
kumpulan pesakit yang menerima perkhidmatan TDM (Kumpulan TDM) dan 
kumpulan yang tidak menerima perkhidmatan tersebut (Kumpulan Tiada TDM). 
Semua kos kemasukan hospital dikira dalam nilai Ringgit Malaysia (RM), 
termasuklah perkhidmatan TDM, penyiasatan makmal dan klinikal, dos gentamisin, 
kakitangan wad, dan tempoh tinggal di hospital. Ukuran hasilan termasuk tempoh 
demam, tempoh tinggal di hospital semasa terapi gentamisin dan kejadian 
nefrotoksisiti. Data dari HUSM menunjukkan kos perkhidmatan TDM 
menyumbangkan lebih kurang 23% kepada jumlah kos kemasukan hospital. Di 
antara kos perkhidmatan TDM, kos alatan makmal adalah yang tertinggi (42%) 
diikuti dengan kos reagen dan alatan pakai habis (39.7%), pasukan TDM (9.6%) dan 
ruang makmal (8.6%). Data dari Hospital Kulim menunjukkan kos yang dikaitkan 
dengan tempoh tinggal di hospital dan jumlah kos kemasukan hospital adalah lebih 
tinggi dan signifikan dalam Kumpulan TDM berbanding dengan Kumpulan Tiada 
TDM. Walau bagaimanapun, tidak terdapat perbezaan yang signifikan dalam lain-
lain parameter hasilan di antara dua kumpulan tersebut.  Sebagai kesimpulannya, 
kajian ini menunjukkan bahawa perkhidmatan TDM disediakan oleh kebanyakan 
hospital di negara ini. Data dari HUSM menunjukkan perkhidmatan ini dalam 
pesakit bronkopneumonia tidak mempengaruhi keseluruhan kos hospital. Data dari 
Hospital Kulim pula menunjukkan perkhidmatan ini meningkatkan jumlah kos 
kemasukan ke hospital dengan signifikan dan tidak memberikan impak yang 
signifikan ke atas hasilan klinikal pesakit. 
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THERAPEUTIC DRUG MONITORING SERVICE IN MALAYSIA: 
CURRENT PRACTICE AND COST EVALUATION 
 
ABSTRACT  
 
Therapeutic drug monitoring (TDM) has been recognized as a useful clinical tool in 
drug therapy. Although it was started in the 1980s in this country, very few studies 
had been performed to evaluate the service. Therefore, this study aims to evaluate the 
practice of the TDM service in Malaysian hospitals and to determine the cost and 
impact on clinical outcomes of providing this service in hospitalized patients. The 
study consists of two related parts. The first part determined the current TDM 
practice among government hospitals in Malaysia using a survey questionnaire. 
Questionnaires were mailed to 128 hospitals in Malaysia. Data were collected for 
general characteristics of the hospitals, administrative, clinical, and laboratory 
activities related to TDM service. Out of 121 hospitals which responded to the 
survey, 34 hospitals (28.1%) provided the service using their own TDM laboratories, 
44 hospitals (36.4%) provided the service using other hospitals’ laboratories and 43 
hospitals (35.5%) did not provide the service at all. The second part of this study was 
conducted to evaluate the cost and clinical outcomes of providing the TDM service 
in hospitalized patients. This evaluation was carried out in two hospitals using 
retrospective data collections. Data from all hospitalized adult patients diagnosed 
with bronchopneumonia and treated with gentamicin between the years 2001 to 2005 
were included. Data collected from Hospital Universiti Sains Malaysia (HUSM) 
were used to determine the cost of providing the TDM service. Data collected from 
Hospital Kulim was used to compare the cost and outcome between the group which 
 xxiii
was provided with the TDM service (TDM group) with the group which was not 
provided with the service (Non-TDM group). All hospitalization costs were 
calculated in Ringgit Malaysia (RM), which included TDM service, laboratory and 
clinical investigations, gentamicin doses, ward staff, and hospital stay. Outcome 
measures included duration of fever, length of hospital stay during gentamicin 
therapy and nephrotoxicity incidence. Data from HUSM show that the cost of TDM 
service contributed about 23% toward the total hospitalization costs. Among TDM 
service costs, the cost of laboratory equipments was the highest (42%) followed by 
reagents and consumables (39.7%), TDM team (9.6%), and laboratory space (8.6%). 
Data from Hospital Kulim show that the costs of hospital stay and total 
hospitalization were significantly higher in the TDM group compared to the Non-
TDM group. However, there was no significant difference in outcome parameters 
between the two groups. In conclusion, this study has shown that TDM service is 
offered by the majority of hospitals in the country. Data from HUSM show that 
providing TDM service to bronchopneumonia patients did not significantly affect the 
overall hospital cost. Data from Hospital Kulim show that TDM service significantly 
increased the total cost of hospitalization and had no significant impact on patients’ 
outcome. 
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CHAPTER ONE 
GENERAL INTRODUCTION 
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1.0 GENERAL INTRODUCTION 
Therapeutic drug monitoring is used in pharmaceutical services to enhance patient 
care. It was first introduced to the clinical practice in the early 1970s. Since the 
initiation of this service, different studies evaluating TDM laboratory activities, 
studying the impact of the service on patient outcome, surrogate endpoints, and 
pharmacoeconomic evaluations have been done worldwide. 
 
TDM service in Malaysia started in 1984 (Hassan, 1990). After more than 20 years 
of experience, 73 hospitals are providing the service (Ministry of Health, 2005). 
Although it started long time ago in Malaysia, very few studies have been performed 
regarding the service. This study has been performed with two main objectives. First 
was to identify the current practice of the service in government hospitals in 
Malaysia. The second objective was to evaluate the cost and benefits of providing the 
service. The study was divided into two parts to achieve each objective separately. 
 
The first part of the study focused on the general provision of the service; 
availability, laboratory procedures, and staff activities. It was performed using a 
survey methodology. The second part evaluated the impact of this service in one of 
the most monitored drugs in Malaysian hospitals on cost and clinical outcome.  This 
second part was carried out in two different hospitals; one university and one public 
hospital. Preliminary findings suggested that patients on gentamicin were always 
provided with TDM service in the university hospital. The cost of providing TDM 
service was compared to other hospital costs in hospitalized patients with 
bronchopneumonia. In the public hospital, not all patients on gentamicin were 
provided with TDM service. In this setting, the benefits (in terms of cost and clinical 
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outcome) of providing TDM service to hospitalized patients with bronchopneumonia 
were calculated. 
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2.1 INTRODUCTION 
2.1.1 Therapeutic Drug Monitoring (TDM) service 
2.1.1(a) Principles of TDM 
Drug concentration in plasma was first analyzed in the late 1950s and early 1960s. 
The measurement was initially carried out for the purpose of research rather than for 
routine clinical service (Pippenger, 1979). Not until when the pharmacological 
activity of a drug was shown to be related to its concentration, did the concentration 
measurement were routinely done (Spector, 1988). 
 
Therapeutic drug monitoring (TDM) is based on the assumption that, if there is a 
relationship between the concentration of a drug in a biological fluid and its effect, 
then the measurement of the biological fluid drug concentrations may be useful for 
patient care (Watson, 1997; Potter, 2000; Gross, 2001; Gram, 2001). It is defined as a 
measurement made in the laboratory, which is applied to a small group of drugs in 
which there is a direct relationship between serum drug concentration and 
pharmacological response (Watson, 1997; Schumacher and Barr, 1998). 
 
The range of drug concentrations most commonly associated with optimal effect and 
an acceptable incidence of toxicity is called the therapeutic range. Pharmacokinetics 
is a mathematical relationship between a drug dosage regimen and the resulting drug 
concentrations. Clinical pharmacokinetic is the application of these mathematical 
principles in conjunction with other measures of clinical observation (Mackichan and 
Comstock, 1986; Nation and Rayner, 2004a). In practice, therapeutic drug 
monitoring makes use of the measurement of drug concentration and clinical 
pharmacokinetics to manage patient drug therapy. 
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2.1.1(b) Clinical applications of TDM 
There are many applications of TDM in clinical setting. TDM is used to evaluate the 
degree of therapeutic response, provide useful information regarding the 
appropriateness of drug therapy, evaluate for patient compliance with drug regimen, 
detect suspected adverse effects, and to confirm drug toxicity (Shirrell, 1999; Gross, 
2001; Pippenger, 2006). It is also useful in confirming drug interactions, diagnosis of 
overdosed patients, and mainly dosage adjustment (Spector et al., 1988). 
 
Very old and very young patients and patients with abnormal organ functions, such 
as renal or hepatic impairments exhibit variation in drug pharmacokinetics. Because 
of these wide variabilities, TDM is a useful tool in dosage individualization in these 
patients (Walson, 1998). 
 
In general, patients that may need to be monitored by TDM service include patients 
with the following characteristics and conditions; renal impairment, hepatic 
impairment, history of hematological abnormalities, marked cardiac dysfunction, 
severe airway disease, diabetes mellitus, obstetric problem, on dialysis, elderly 
patients, children and neonates, obese and malnourished, and burn patients. Those 
patients who receive drugs that have narrow therapeutic index, high incidence of 
adverse effects, high incidence of drug interactions, drugs that may induce reactions 
or hypersensitivity, or newly marketed drugs can also be included (Malaysian 
Ministry of Health, 2001). 
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2.1.1(c) TDM process 
The TDM team includes clinical pharmacologists, clinical pharmacists and analytical 
scientists as well as other personnel who participate in patient care such as doctors 
and nurses (Gross, 2001; Shenfield, 2001). Doctors usually request TDM tests for 
specific patients according to some specific indications. The nurse is responsible for 
collecting the blood samples for analysis. Performing the TDM tests is mainly a 
responsibility of the analytical scientist or technician who is well trained and 
qualified for this process. After performing the tests and obtaining the results, the 
clinical pharmacologist or pharmacist interprets these results and converts them into 
useful information and recommendations to the requested doctor (Koren et al., 1985; 
Gross, 2001). 
 
Figure 2.1.1 shows a TDM process adapted from Barr and Schumacher (1995). The 
TDM process consists of four main components that begins and ends with patient 
care; pre-analytical, analytical, post-analytical, and the regulatory environment. 
Regulatory environment is the condition and atmosphere that surrounds the 
analytical procedure. The pre-analytical component consists of 4 steps; the first step 
starts with the clinical question that arises when the clinician comes across the 
patient. In the next step, the clinician chooses the test(s) that might answer this 
question. The clinician orders the test in the third step. At the end of this component, 
the sample is taken and sent to the clinical laboratory for analysis. 
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Regulatory Environment 
 
Figure 2.1.1 TDM process (adapted from Barr and Schumacher, 1995) 
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The first step is the sample preparation, which consists of transporting the sample to 
the analysis site and separation of serum or plasma from cellular blood to prepare it 
for analysis. The second step is performing the analysis using an appropriate assay 
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The third component has four steps. The first step is reporting the result by either 
hard or soft copy or both. In the second step, this result is expected to give an answer 
for the previous clinical question raised in the first component. In the last two steps 
of this component, the clinician can take action accordingly to meet the patient care 
needs. 
 
2.1.1(d) Sample matrices 
Usually drugs are monitored in venous blood, serum or plasma. Whole blood may be 
used for some drugs like cyclosporine, tacrolimus, sirolimus, and everolimus which 
distribute between erythrocytes and plasma (Gross, 2001; Dasgupta, 2008). Saliva 
can be used instead of blood in case of infants and children (Zalzstein et al., 2003). 
In addition, saliva can be used in the elderly and pregnant women and sometimes in 
adult patients when venipuncture is difficult. It can be easily collected and preferred 
by the medical staff as it minimizes their contact to blood samples (Barr and 
Schumacher, 1995). Drugs that can be monitored using saliva are phenytoin, 
carbamazepine, theophylline, digoxin, and lithium. In addition, drugs of abuse such 
as morphine and cocaine can also be monitored by saliva (Pichini, 1996). 
 
Using urine as a biological matrix for drug monitoring has many advantages. Urine 
samples can be easily collected and are well accepted by patients. Moreover, urine is 
preferred because its window for identifying drug use is broader compared to blood. 
The use of urine in TDM service is applicable to anticonvulsant and psychoactive 
drugs (Elmquist, 1991; Wu, 1998). 
 
 10
There are some other biological matrices that can be used but to a lesser extent such 
as tears, which can easily be collected. It seems to be more homogenous and more 
constant in their composition than saliva. Due to its pH, only unionized and acidic 
drugs with high pKa values distribute in tears in a predictable manner, which limits 
its use to small variety of drugs like valproic acid (Pichini, 1996; Nakajima et al., 
2000). 
 
Hair as a biological matrix can keep drugs and metabolites indefinitely, in contrast to 
serum or urine in which drug concentrations decrease rapidly with time. Therefore, 
hair can be used for forensic purposes as well as in drugs of abuse. Hair testing has 
some drawbacks due to the difficulty in producing reference material for laboratory 
practices and to the differences in hair characteristics from one patient to another. 
Similar to hair, nails are used in drug abuse and forensic examination. Moreover, 
they can be used in antifungal drugs monitoring. Recently, sweat is being used for 
determination of drugs of abuse although sampling procedure and method of analysis 
are very complicated (Pichini, 1996; Palmeri et al., 2000; Pragst and Balikova, 
2006). Moreover, sweat is another biological matrix that can be used in forensic 
examination for detection of drugs of abuse. It can be used in nonvolatile drugs like 
heroin. The sampling procedure is an easy process, which applied by using sweat 
patches. It is a noninvasive procedure, requires minimal handling by the operator and 
is acceptable by patients (Fucci and Giovanni, 2007). 
 
Many studies that are conducted for bile measurement were carried out for patients 
who have previously undergone biliary tract surgery. Penicillins, cephalosporins, 
aminoglycosides, and cardiac glycosides are some drugs that have been determined 
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using bile analysis. Feces are limited to studies in new drug development and may 
provide information on excretion of drugs and metabolites through its route of 
excretion (Pichini, 1996). 
 
Fetus blood and amniotic fluid can be used for detecting of drugs that can affect the 
fetus such as some antibiotics, anticonvulsants and tranquillizers. Additionally, the 
importance of drug investigation in breast milk is to determine the amount of drug 
that can be ingested by the breastfeeding infant. Phenobarbital, theophylline, and 
some psychoactive drugs as well as drugs of abuse might be detected in breast milk 
(Pichini, 1996; Loebstein and Koren, 2002; Moretti et al., 2003). 
 
Drug measurement in cerebrospinal fluid (CSF) is necessary to establish if the 
concentration of a drug in the central nervous system (CNS) is desirable for the drug 
effect or not. Collection of CSF is not an easy technique since it is done by lumbar 
puncture. Examples of drugs that are monitored by CSF measurement are antibiotics 
that are used in CNS infections, anticonvulsants, psychoactive drugs, and protease 
inhibitors (Pichini, 1996; Aarnoutse et al., 2001). 
 
Monitoring of drugs in bronchial secretions and peritoneal fluid are rarely used. They 
are used for patients with serious diseases and require invasive techniques for sample 
collection. Using interstitial fluid as a biological matrix in neonates may provide 
information regarding the toxic agents that may be absorbed through the skin. It can 
be used for analgesics and theophylline that may be applied transdermally. Drug 
concentration monitoring in cervical mucus is mainly carried out for 
pharmacotoxicological purposes. For example, it is used to detect the presence of 
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nicotine and its metabolite in the cervix due to its risk of cervical neoplasia. 
Examining the seminal fluid is used to determine the presence and concentrations of 
some drugs that may affect the physiology or activity of semen in man as well as the 
pharmacological and adverse drug reaction in women exposed to drugs excreted in 
semen. Drugs like antimicrobials, sulfasalazine, salicylate, propranolol, and protease 
inhibitors are monitored in the seminal fluid (Pichini, 1996; Aarnoutse et al., 2001). 
 
2.1.1(e) Analytical techniques used in TDM 
In the late 1950s and early 1960s, Ultraviolet Spectrophotometry was the first 
method applied for the analysis of drug concentration in the plasma but it has some 
disadvantages. It required large volume samples as well as extraction techniques 
were time consuming and complex. It is considered as the most used technique for 
the determination of methotrexate (Pippenger, 1979; Rubino, 2001). 
 
In the middle of 1960s, Gas-Liquid Chromatography (GLC) was introduced as a 
method of separating classes of drugs rapidly and quantitatively at the same time but 
its main disadvantage was the complexity of its instrumentation. In 1970s, GLC was 
performed routinely in clinical chemistry laboratories and it is used to measure the 
concentrations of some antidepressant drugs (Pippenger, 1979; Lacassie et al., 2000). 
 
Radioimmunoassay (RIA) technique was the first immunoassay technique that is 
used in drug monitoring. It has an advantage that it can measure drug concentration 
in microvolumes. It has some disadvantages of complexity of its instrumentation as 
well as time consuming procedure, disposal of radioactive waste, and short shelf-life 
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of its reagents. It can be used to detect digoxin (Pippenger, 1979; Barr and 
Schumacher, 1995). 
 
An automated, homogeneous Enzyme Immunoassay Techniques (EMIT) was 
available in 1970s which enables TDM service to be available to all laboratories. 
However, it is limited to those drugs for which antibodies are available. It uses a 
simple technology and has rapid turnaround time with a high accuracy rate. Enzyme-
Linked Immunosorbent Assay technique (ELISA) has almost the same technique as 
other enzyme immunoassays. Separation steps are required for completing the 
analytical procedure and that is why ELISA is called a heterogeneous method. 
Besides, it is limited to those drugs that antibodies are available (Pippenger, 1979; 
Sym et al., 2001). 
 
High Pressure Liquid Chromatography (HPLC) solves a lot of problems regarding 
the assay of multiple drugs and their metabolites within the same class. It can be 
applied for many drugs but it has the disadvantages associated with the high 
turnaround time and that highly skilled personnel are needed to perform the 
procedures (Pippenger, 1979; Barr and Schumacher, 1995; Jebabli et al., 2007). 
However, it is used to some extent in teaching hospitals and for research purposes 
(Gogtay et al., 1999). In the late 1990s, Turbulent Flow Chromatography (TFC) a 
new chromatographic technique was introduced. It is a fully automated and simple 
technique. It requires short time for sample preparation and analysis. Mainly it is 
used for monitoring antidepressant drugs and their metabolites (Sauvage et al., 
2006). 
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Fluorescence Polarization Immunoassay (FPIA) is now the most widely used 
technique worldwide. It is easy to perform, does not need highly skilled personnel 
and has shorter turnaround time. Like other immunoassay techniques, measuring 
serum drug concentration is based on an antigen-antibody reaction. FPIA technique 
has some drawbacks such as in some drugs like cyclosporine, where metabolites 
interfere with the reagents’ antibodies; and the high cost of its reagents used in the 
drug analysis (Lee et al., 1991; Morris, 1994; Barr and Schumacher, 1995; Sym et 
al., 2001). Other techniques that are rarely used in TDM service include Flame 
emission/absorption methods. These method are used to measure the concentration of 
drugs like lithium (Thomson et al., 1998). 
 
2.1.1(f) Drugs monitored and sampling time 
Drugs monitored by TDM service share some characteristics either they have 
relatively narrow therapeutic range (TR), or a conventional dose response 
relationship is deficient (Cuddy, 2000). Others have pharmacological action that is 
difficult to be measured clinically (McInnes, 1989). Wolf (1996) has proposed the 
criteria for drugs that should be monitored by TDM service. They include drugs with 
dangerous toxicity, have narrow therapeutic range, are used in long term therapy, are 
used in life threatening disease, have interindividual pharmacokinetic variability, 
drugs with nonlinear pharmacokinetics, drugs with wide distribution in the body, and 
the availability of reliable analytical techniques to measure the drug’s concentration. 
Ideally, the drug should be monitored only when it reaches steady state. However, 
plasma concentration can be measured before steady state in some cases, but still 
sampling time should be taken into consideration. Sampling time varies with 
different drugs. To optimize the drug concentration values, blood samples should be 
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taken at specific times with respect to the last dose taken. Usually drugs are 
measured just before the last dose (trough level). Aminoglycosides and vancomycin 
are measured at the trough level and the peak (after giving the last dose) level 
(Aronson and Hardman, 1993b). 
 
Aminoglycosides like gentamicin (TR peak = 4-8 µg/ml, TR trough = 1-2 µg/ml), 
amikacin (TR peak = 15-25 µg/ml, TR trough < 5 µg/ml), and tobramycin (TR peak 
= 4-8 µg/ml, TR trough =1-2 µg/ml), have the same characteristics and they all have 
a narrow therapeutic index. Moreover, their mechanism of action depends directly on 
the peak drug concentration in the serum, while the ototoxicity and nephrotoxicity 
are related mainly to the total amount of drug given. TDM may be useful in keeping 
the aminoglycosides within the therapeutic range while avoiding toxicity (Triggs and 
Charles, 1999; Dasgupta, 2008). If the drug is given by IV infusion, the sample 
should be taken after 15 minutes at the end of the infusion for post-therapy 
measurement. In case of pre-therapy measurement the sample should be taken just 
before the next dose. In patients with normal renal function, gentamicin 
concentration measurement should be carried out within the first 24 hours of 
treatment to optimize drug therapy (Aronson and Reynolds, 1993a). 
 
Vancomycin (TR peak = 30-40 µg/ml, TR trough = 5-15) has almost the same side 
effects as aminoglycosides. But it has a different mechanism of action with a so 
called time-dependent killing, which works better when its trough concentration in 
the site of infection is higher than the minimum inhibitory concentration (MIC) of 
the infected organism. Its concentration-independent mechanism has raised 
considerable arguments regarding the benefits of measuring the vancomycin 
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concentration. However, not all patients with vancomycin require concentration 
monitoring. The peak level of vancomycin should be taken within half to one hour 
after completing the one hour infusion to allow the completion of the distribution 
phase (Begg et al., 1999; Bauer, 2001; Dasgupta, 2008). 
 
Anticonvulsants like phenytoin (TR= 10-20 µg/ml), phenobarbital (TR= 15-40 
µg/ml), valproic acid (TR= 50-100 µg/ml), ethosuximide (TR= 40-75 µg/ml), and 
carbamazepine (TR= 4-12 µg/ml), are generally monitored in plasma or serum 
because the concentrations are identical in these two biological matrices (Eadie, 
2001; Dasgupta, 2008). Phenytoin lacks a predictable dose-response relationship, and 
serum drug concentration measurement has proved to be a better indicator of clinical 
response (Cuddy, 2000). The concentration of phenytoin should be measured after a 
few days of starting the treatment but practically, the concentration is measured after 
three to four weeks of continuous dosing (Aronson et al., 1993a). Other drugs also 
should be monitored when they reach steady states. For example, phenobarbital is 
monitored after 3-4 weeks, carbamazepine after 2-3 weeks and valproic acid on the 
second day. However, patients should be monitored in case of worsening of epilepsy 
or when they have signs of drug toxicity (Bauer, 2001). 
 
Theophylline (TR= 10-20 µg/ml) shares the same criteria of lacking a predictable 
dose response relationship. Theophylline concentrations may provide diagnostic and 
predictive information about therapy in overdose cases (Cuddy, 2000; Dawson and 
Whyte, 2001; Dasgupta, 2008). In case of IV infusion, the sample should be taken 
after 4-6 hours of infusion; the infusion should be stopped for 15 minutes before 
taking the sample (Aronson et al., 1993b). 
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Monitoring of digoxin (TR= 0.8-2.0 ng/ml) can be useful in controlling the 
therapeutic or toxic effect. Steady state of digoxin can be reached, in case of normal 
renal function, after eight days of treatment. Digoxin sampling may be carried out at 
least six hours after the last dose or just before the next dose (Cuddy, 2000; Aronson 
and Hardman, 1993a; Dasgupta, 2008). 
 
The narrow therapeutic ratio along with the variation in the pharmacokinetics of 
immunosuppressant drugs such as cyclosporine (TR= 100-400 ng/ml), tacrolimus 
(TR= 5-15 ng/ml), sirolimus (TR= 4-20 ng/ml), everolimus (TR= 5-15 ng/ml), and 
mycophenolic acid (TR= 1-3.5 µg/ml) from one person to another highlighted the 
importance of individualizing the drug therapy using TDM service. TDM service is 
useful to avoid the rejection of the transplant organ in case of the subtherapeutic 
levels and to prevent the toxic effects of the drug in case of drug overdose. 
Cyclosporine sample should be taken before the next dose (Reynolds and Aronson, 
1993; Dasgupta, 2008). 
 
Lithium (TR= 0.8-1.2 µEq/l) has a narrow therapeutic ratio and its pharmacokinetics 
vary from one patient to another. This makes it difficult to accurately predict the 
dosage regimen of this drug. Lithium samples should be taken after 12 hours from 
the last dose (Aronson and Reynolds, 1993b; Dasgupta, 2008). 
 
Because of their potential toxicities, serum concentration of drugs like salicylates, 
ethanol and paracetamol are monitored in some hospitals in all patients who are 
presented with mental problem (Wu, 1998). Paracetamol should be monitored in all 
patients who ingested large amount or unsafe dose of the drug. Due to high 
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variability in its pharmacokinetics and metabolic profile in children and neonates, 
paracetamol should be monitored to avoid the subtherapeutic and toxic 
concentrations. Paracetamol sample should be taken at least 4 hours after ingestion of 
the drug (Dawson and Whyte, 2001; Oliveira et al., 2002). 
 
Other drugs that are also monitored by TDM service include amiodarone (TR= 1-2.5 
µg/ml), quinidine (TR= 2-5 µg/ml), procainamide (TR= 4-10 µg/ml), and lidocaine 
(TR= 1.5-5 µg/ml), methotrexate (TR> 0.01 µicromol), caffeine (TR= 5-15 µg/ml), 
disopyramide (TR= 1.5-5 µg/ml), and some antituberculin drugs (Gogtay et al., 
1999; Baylor, 2007; Dasgupta, 2008). 
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2.1.2 Literature review of TDM service 
TDM service is a widely used clinical service all over the world. However, among 
hospitals and institutions which provide this service there are variations in the 
availability, number and source of samples, analytical and clinical activities, 
participation in quality assurance programs, and educational programs offered. 
 
2.1.2(a) TDM service in developed countries 
In Australia TDM service was started in the late 1970s and the early 1980s 
(Shenfield, 2001). Although TDM service started a long time ago, there are still 
many hospitals that do not provide this service while others provide it partially with 
the assistance of other institutions. However, until the late 1990s, about 75% of 
hospitals in Australia provided TDM service. About 65% of these hospitals perform 
drug assay measurements in their own laboratories (Morris, 1998). A survey 
performed by Morris (1994) looking at cyclosporine-A (CsA) monitoring, reported 
that 93% of TDM laboratories in Australia perform more than 500 CsA tests 
annually; 10% of these tests were received from external sources rather than the unit 
that offer the analysis. Most of these laboratories were not included in external 
quality assurance programs. They use different types of reporting procedures 
included phone calls, online computer system, and face-to-face communications 
(Morris, 1994). The number of cyclosporine-A samples that monitored in these 
laboratories increased up to 12770 samples in the year 2000, while the number of 
laboratories that registered in the International Proficiency Testing Scheme increased 
to 71% (Morris and Lam, 2002). 
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In Spain, TDM service was started in 1980. The majority of TDM units in the 
country began their services in the biochemistry department. The biochemistry 
department provides the results while the central pharmacology unit in the hospital 
provides the recommendations to the doctors. Vall d’Hebron is a public institution 
that covers four main hospitals and receives samples from other outpatient clinics 
with an average of 8800 tests performed in 1990. The service is available for 12 
hours daily, Mondays through Fridays except for emergency and some specific cases 
that had to be performed during weekends. Drugs monitored by the TDM service are 
anticonvulsants, aminoglycosides, vancomycin, theophylline, and cyclosporine (Pou 
and Campos, 1992). 
 
In the Netherlands, TDM service started in the early 1980s. It is performed mainly by 
the hospital pharmacist and it is a part of the pharmacy department in hospitals. 
Vinks et al. (1992) reported that in The Hague Hospitals Central Pharmacy 
incorporated many different pharmaceutical services including TDM service. This 
centre performs the TDM service for all participating local hospitals in the area for 
an average of 12000 samples carried out each year. The service is available seven 
days a week and operates 24 hours daily. The most common drugs monitored are 
aminoglycosides and theophylline (Vinks et al., 1992). 
 
Murphy et al. (1996) reported that the TDM service first started in USA in the 1970s. 
TDM service was available during the daily working hours, Mondays to Fridays in 
most hospitals. Twenty four hours-a-day services and on-call services were available 
in a few hospitals only. Aminoglycosides, vancomycin, theophylline, and 
cyclosporine, digoxin, antiepileptic drugs, lithium, methotrexate, caffeine, 
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ethosuximide, warfarin, and procainamide are the common drugs monitored by the 
TDM service. TDM pharmacists participated in continuous educational programs to 
increase their skills and competence (Murphy et al., 1996). 
 
In the state of Georgia, TDM service was available in 23.3% of hospitals. TDM 
laboratory was a part of the pharmacy department in 93% of the hospitals. Drugs 
monitored were aminoglycosides, vancomycin, theophylline, cyclosporine, digoxin, 
antiepileptic drugs, lithium, methotrexate, warfarin, and procainamide. An average of 
1000 samples was performed annually in some hospitals (Murphy et al., 1991). 
 
Howard et al. (1994) found that 70% of all veterans affairs medical centre in USA 
provided TDM service. The majority (82%) of hospitals started providing the service 
within the last nine years before this survey. However, more than half (68%) of 
hospitals in veterans affairs started providing the service since 1990. In a recent 
national survey, Pedersen et al. (2000) reported that 75% of hospitals in USA 
provide TDM service for inpatients. The pharmacists in these hospitals routinely 
provided recommendations for adjusting and calculating the dosage for those drugs 
that are monitored in their hospitals.  
 
In Japan, TDM service started in Kyushu University Hospital in 1981. The pharmacy 
department provides the service within their own TDM laboratory which is located in 
the hospital. An average of 4350 requests was performed annually in the unit. The 
sources of these samples were mainly from inpatient and outpatient clinics. 
Antiepileptics, aminoglycosides, theophylline, digitals, lithium, methotrexate, and 
disopyramide were the most common drugs monitored by the unit (Ieiri et al., 1990). 
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In Canada, TDM service started in the Hospital of Sick Children in 1981. The TDM 
laboratory was managed by a clinical pharmacist of the clinical pharmacology 
division. The service was available seven days a week, 24 hours a day. Thirteen 
different drugs (antibiotics, cardiovascular drugs, anticonvulsants, theophylline, and 
methotrexate) were monitored daily in the hospital, with an average of 19200 
samples performed yearly. It was found that the service had an impact of decreasing 
the toxic level of drugs monitored (Koren, 1985). 
 
A survey of 157 TDM laboratories, mainly from Europe, Asian and African 
countries found that different reporting procedures were used in these laboratories. 
They ranged from producing hard copy reports, phone calls, and fax, to using online 
computer reporting. Some of these laboratories reported that insufficient information 
in the TDM request form was the main problem faced by the TDM service (Thomson 
et al., 1998). 
 
2.1.2(b) TDM service in developing countries 
In Iran, TDM service first started in 1984 at the Tehran University of Medical 
Sciences Hospital. Drug samples were analyzed at their own TDM laboratory, which 
was located in the hospital. Samples were received from their own hospital 
departments as well as from other clinics and neighboring hospitals. Phenobarbital 
and phenytoin were the first drugs monitored by the TDM unit. Many other drugs 
were included later on to be monitored by the service (Bigdeli, 1992). 
 
TDM service was started first in Turkey in the late 1980s by the Pharmacology 
department in Istanbul Medical Faculty Hospital. Eighty-four percent of the samples 
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came from their hospital departments and 16% came from other hospitals. More than 
5500 tests were monitored annually by the TDM unit. Drugs monitored were 
antiepileptics, digoxin, theophylline, and salicylates (Yamantürk et al., 2000). 
 
In South Africa, Cridland (1994) reported that TDM service was performed mainly 
by the pharmacology and biochemistry departments of the Groote Schuur Hospital 
(1470 beds). They performed about 20,300 samples annually. Seventy percent of 
these samples came from the hospital departments while the rest came from other 
medical institutions. Common drugs monitored by the hospital included theophylline, 
digoxin, antiepileptics, and cyclosporine. 
 
In developing countries like Saudi Arabia and Egypt, evaluation of TDM service has 
been performed. Desoky et al. (2003) evaluated the impact of TDM service on the 
distribution of the drug concentrations. They found no differences in the rates of 
subtherapeutic, therapeutic or toxic drug levels for digoxin, carbamazepine, 
phenytoin, and valproic acid between the two countries. 
 
2.1.2(c) TDM service in Malaysia 
Malaysia is located in South East Asia with an area of 329,750 square kilometer. It 
has a population of 23,953,136 (Information Centre Malaysia, 2005). The first TDM 
service in Malaysia was offered by the School of Pharmaceutical Sciences in the 
Hospital Universiti Sains Malaysia (HUSM) in the year 1984 (Hassan, 1993). 
Gentamicin was the first drug monitored by TDM service in HUSM (Ismail, 1990). 
Commonly monitored drugs in HUSM were paracetamol, aspirin, theophylline, 
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aminoglycosides, vancomycin, antiepileptic drugs, digoxin, chloroquine, mefloquine, 
and procainamide (Hassan, 1990). 
 
In 1987, only four hospitals provided the TDM service. The number of hospitals that 
provided the service increased to 9, 20, 61, and 73 in the years 1988, 1992, 2002, and 
2005 respectively. Fourteen drugs are regularly monitored in government hospitals, 
which include aminoglycosides, antiepileptics, digoxin, theophylline, cyclosporine, 
methotrexate, tacroloimus, vancomycin, and lithium. The total number of cases 
monitored increased from 25,756 in 1998 to 61,907 in 2005 (Ministry of Health, 
1988, 1992, 2002a, 2005a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
